Medicare HMO Penetration and Mortality Outcomes of Ischemic StrokeByJohn Bian, PhD,William H. Dow, PhD,David B. Matchar, MDJanuary 1st 2006
Who Will Be Denied Medicare Prescription Drug Subsidies Because of the Asset Test?ByThomas Rice, PhD,Katherine Desmond, MSJanuary 1st 2006
Medicare and Medicaid Managed Care: A Tale of Two TrajectoriesByRobert E. Hurley, PhD,Sheldon M. Retchin, MDJanuary 1st 2006
Do Drug Formulary Policies Reflect Evidence of Value?ByPeter J. Neumann, ScD,Pei-Jung Lin, MS,Dan Greenberg, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD,Edward Mansley, PhD,Milton C. Weinstein, PhD,Allison B. Rosen, MD, ScDJanuary 1st 2006
Varying Pharmacy Benefits With Clinical Status: The Case of Cholesterol-lowering TherapyByDana P. Goldman, PhD,Geoffrey F. Joyce, PhD,Pinar Karaca-Mandic, PhDJanuary 1st 2006
Value-based Insurance Design: A "Clinically Sensitive" Approach to Preserve Quality of Care and Contain CostsByA. Mark Fendrick, MD,Michael E. Chernew, PhDJanuary 1st 2006
